At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg) +2 morebiological
Likely dose
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)
In Brief
A Phase 2 clinical trial evaluating IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, and 1 other intervention for Hepatocellular Carcinoma. Completed, enrolled 47 participants across 7 sites.
Detailed Summary
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedMay 2009
Primary CompletionOct 2012
Study CompletionMay 2014
TodayJul 2026
First PostedMay 21, 2009
Enrollment StartMay 1, 2009
Primary CompletionOct 1, 2012
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 17.1 years ago
Interventions
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)biological
intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
IMC-A12 (cixutumumab) - 20 mg/kgbiological
intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
Sorafenibdrug
400 milligrams (mg) twice per day orally